Jad Chahoud, MD, MPH, discusses the safety profile of ALLO-316 for the treatment of patients with advanced clear cell renal carcinoma.
Jad Chahoud, MD, MPH, MHA
Advertisement
Jad Chahoud, MD, MPH, MHA, is an associate member in the Department of Genitourinary Oncology and medical director of IPOP at Moffitt Cancer Center.
Articles by Jad Chahoud, MD, MPH, MHA
Jad Chahoud, MD, MPH, discusses the CAR T-cell therapy ALLO-316 in advanced clear cell renal carcinoma (ccRCC).
Jad Chahoud, MD, MPH, discusses the background and rationale for evaluating zanzalintinib plus nivolumab with or without relatlimab in ccRCC.
Jad Chahoud, MD, MPH, MHA, shares early-phase data with zanzalintinib plus nivolumab with or without relatlimab-rmbw in previously untreated ccRCC.
Advertisement
Latest Updated Articles
Dr Chahoud on Early Efficacy With Zanzalintinib Plus Nivolumab With/Without Relatlimab in ccRCCPublished: May 31st 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5